Bustany Sophie, Cahu Julie, Descamps Géraldine, Pellat-Deceunynck Catherine, Sola Brigitte
Normandie Univ, UNICAEN, EA4652, Caen, France.
CRCNA, INSERM U892, CNRS UMR6299, Université de Nantes, Nantes, France.
J Hematol Oncol. 2015 Apr 23;8:40. doi: 10.1186/s13045-015-0135-3.
Deregulated expression of heat shock proteins (HSPs) encoding genes is frequent in multiple myeloma. HSPs, which are molecular chaperones involved in protein homeostasis pathways, have emerged recently as promising therapeutic targets. Using human myeloma cell lines and primary myeloma cells belonging to various molecular groups, we tested the efficacy of HSP90, HSP70, and heat shock factor 1 (HSF1) inhibitors alone or associated with current antimyeloma drugs. We report here that KNK-437 (an inhibitor of HSF1) and bortezomib have additive effects on apoptosis induction in cells belonging to groups with bad prognosis.
热休克蛋白（HSPs）编码基因的失调表达在多发性骨髓瘤中很常见。HSPs是参与蛋白质稳态途径的分子伴侣，最近已成为有前景的治疗靶点。我们使用属于不同分子组的人骨髓瘤细胞系和原发性骨髓瘤细胞，测试了HSP90、HSP70和热休克因子1（HSF1）抑制剂单独使用或与当前抗骨髓瘤药物联合使用的疗效。我们在此报告，KNK - 437（一种HSF1抑制剂）和硼替佐米对预后不良组细胞的凋亡诱导具有相加作用。
